Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

About Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SUPN
  • CUSIP: 86845910
  • Web: www.supernus.com
Capitalization:
  • Market Cap: $2.21 billion
  • Outstanding Shares: 50,699,000
Average Prices:
  • 50 Day Moving Avg: $42.54
  • 200 Day Moving Avg: $34.58
  • 52 Week Range: $17.25 - $46.45
P/E:
  • Trailing P/E Ratio: 23.03
  • Foreward P/E Ratio: 26.20
  • P/E Growth: 1.42
Sales & Book Value:
  • Annual Revenue: $252.59 million
  • Price / Sales: 8.73
  • Book Value: $4.52 per share
  • Price / Book: 9.62
Profitability:
  • EBIDTA: $82.36 million
  • Net Margins: 41.10%
  • Return on Equity: 30.73%
  • Return on Assets: 19.48%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 1.94%
  • Quick Ratio: 1.74%
Misc:
  • Average Volume: 644,873 shs.
  • Beta: 1.31
  • Short Ratio: 5.53
 

Frequently Asked Questions for Supernus Pharmaceuticals (NASDAQ:SUPN)

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.08. The business earned $75.83 million during the quarter, compared to analysts' expectations of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. View Supernus Pharmaceuticals' Earnings History.

Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2017?

6 equities research analysts have issued 12 month price objectives for Supernus Pharmaceuticals' stock. Their forecasts range from $46.00 to $51.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $48.33 in the next twelve months. View Analyst Ratings for Supernus Pharmaceuticals.

What are analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (7/18/2017)
  • 2. Jefferies Group LLC analysts commented, "Following Monday's Zydus settlement, SUPN reached a similar agreement with TEVA on the Trokendi XR (TXR) patent challenge ' allowing generic entry starting January 2023. There is now much more certainty in SUPN's ability to maintain cash flows from 76% of its current epilepsy franchises at least through 2022 and another 24% through 2027 (OXR), bridging to the latestage pipeline, which should come online in 2020. Importantly, SUPN fits with our M&A thesis." (3/8/2017)
  • 3. Cantor Fitzgerald analysts commented, "SUPN announced the settlement of a Paragraph 4 challenge to Trokendi XR patents by Zydus allowing generic entry on or before 1/1/2023." (3/7/2017)

Who are some of Supernus Pharmaceuticals' key competitors?

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the folowing people:

  • Charles W. Newhall III, Independent Chairman of the Board
  • Jack A. Khattar, President, Chief Executive Officer, Secretary, Director
  • Gregory S. Patrick, Chief Financial Officer, Vice President
  • Stefan K. F. Schwabe M.D. Ph.D., Executive Vice-President - Research and Development, Chief Medical Officer
  • Padmanabh P. Bhatt Ph.D., Senior Vice President - Intellectual Property, Chief Scientific Officer
  • Victor Vaughn, Senior Vice President - Sales and Marketing
  • Georges Gemayel Ph.D., Independent Director
  • Frederick M. Hudson CPA, Independent Director
  • William A. Nuerge, Independent Director
  • John M. Siebert Ph.D., Independent Director

Who owns Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.31%), Vanguard Group Inc. (6.93%), Acadian Asset Management LLC (3.10%), Bank of New York Mellon Corp (3.08%), State Street Corp (2.76%) and Rice Hall James & Associates LLC (2.71%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, M James Barrett and Padmanabh P Bhatt. View Institutional Ownership Trends for Supernus Pharmaceuticals.

Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Falcon Point Capital LLC, Northpointe Capital LLC, BNP Paribas Arbitrage SA, Bank of New York Mellon Corp, Cornerstone Capital Management Holdings LLC., Fiera Capital Corp, Menta Capital LLC and Gotham Asset Management LLC. Company insiders that have sold Supernus Pharmaceuticals stock in the last year include Gregory S Patrick and Padmanabh P Bhatt. View Insider Buying and Selling for Supernus Pharmaceuticals.

Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Hodges Capital Management Inc., Rice Hall James & Associates LLC, Royal Bank of Canada, Mesirow Financial Investment Management Equity Management and Prudential Financial Inc.. View Insider Buying and Selling for Supernus Pharmaceuticals.

How do I buy Supernus Pharmaceuticals stock?

Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $43.50.


MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $48.33 (11.11% upside)

Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Piper Jaffray CompaniesReiterated RatingHold -> NeutralMediumView Rating Details
8/4/2017Jefferies Group LLCReiterated RatingBuy$51.00MediumView Rating Details
8/3/2017Cowen and CompanyReiterated RatingOutperform -> Positive$40.00 -> $50.00HighView Rating Details
7/18/2017Stifel NicolausReiterated RatingBuy$36.00 -> $47.00MediumView Rating Details
7/14/2017Janney Montgomery ScottInitiated CoverageNeutral -> Neutral$47.00LowView Rating Details
7/5/2017Cantor FitzgeraldBoost Price TargetBuy$34.00 -> $49.00MediumView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00N/AView Rating Details
(Data available from 8/17/2015 forward)

Earnings

Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings History by Quarter for Supernus Pharmaceuticals (NASDAQ SUPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017$0.24$0.32$68.54 million$75.83 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.22$0.19$57.91 million$57.58 millionViewListenView Earnings Details
8/2/2016Q2$0.13$0.18$49.67 million$50.40 millionViewListenView Earnings Details
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)
2017 EPS Consensus Estimate: $0.97
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.16$0.24$0.20
Q2 20172$0.23$0.25$0.24
Q3 20172$0.27$0.29$0.28
Q4 20172$0.23$0.26$0.25
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 92.80%
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Padmanabh P BhattVPSell3,709$45.23$167,758.07View SEC Filing  
7/12/2017Padmanabh P BhattVPSell3,735$44.90$167,701.50View SEC Filing  
6/23/2017Padmanabh P BhattVPSell2,556$44.90$114,764.40View SEC Filing  
6/2/2017Padmanabh P BhattVPSell10,000$39.86$398,600.00View SEC Filing  
5/26/2017Padmanabh P BhattVPSell2,500$35.90$89,750.00View SEC Filing  
5/25/2017Padmanabh P BhattVPSell5,500$34.90$191,950.00View SEC Filing  
4/24/2017Gregory S PatrickCFOSell54,000$32.37$1,747,980.00View SEC Filing  
4/24/2017Padmanabh P BhattVPSell11,806$32.59$384,757.54View SEC Filing  
9/16/2016Gregory S PatrickCFOSell2,000$25.00$50,000.00View SEC Filing  
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.38View SEC Filing  
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.20View SEC Filing  
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20View SEC Filing  
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.65View SEC Filing  
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.00View SEC Filing  
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.00View SEC Filing  
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00View SEC Filing  
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.85View SEC Filing  
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Supernus Pharmaceuticals (NASDAQ:SUPN)
Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
Source:
DateHeadline
americanbankingnews.com logoPadmanabh P. Bhatt Sells 3,709 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock
www.americanbankingnews.com - August 16 at 10:44 PM
finance.yahoo.com logoSupernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US : August 15, 2017
finance.yahoo.com - August 16 at 7:54 AM
finance.yahoo.com logoSupernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : August 15, 2017
finance.yahoo.com - August 16 at 7:54 AM
feeds.benzinga.com logoSupernus Defeats Second Generic Challenger to Oxtellar XR®
feeds.benzinga.com - August 15 at 5:23 PM
americanbankingnews.com logoAnalysts Set Expectations for Supernus Pharmaceuticals, Inc.'s Q4 2017 Earnings (SUPN)
www.americanbankingnews.com - August 14 at 6:20 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
finance.yahoo.com - August 10 at 8:25 AM
americanbankingnews.com logoFY2019 Earnings Forecast for Supernus Pharmaceuticals, Inc. Issued By Jefferies Group (NASDAQ:SUPN)
www.americanbankingnews.com - August 9 at 2:32 PM
americanbankingnews.com logoCantor Fitzgerald Analysts Lower Earnings Estimates for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
www.americanbankingnews.com - August 9 at 8:36 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Will Post Quarterly Sales of $76.19 Million
www.americanbankingnews.com - August 9 at 7:44 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Supernus Pharmaceuticals, Inc. Increased by Analyst (SUPN)
www.americanbankingnews.com - August 8 at 7:08 AM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Earnings of $0.26 Per Share
www.americanbankingnews.com - August 7 at 8:54 AM
americanbankingnews.com logoPiper Jaffray Companies Reiterates Neutral Rating for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
www.americanbankingnews.com - August 5 at 4:18 PM
seekingalpha.com logoSupernus Pharmaceuticals' (SUPN) CEO Jack Khattar on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 5 at 7:30 AM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
www.americanbankingnews.com - August 5 at 7:14 AM
globenewswire.com logoSupernus Announces Record Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 4 at 8:40 AM
finance.yahoo.com logoEdited Transcript of SUPN earnings conference call or presentation 3-Aug-17 1:00pm GMT
finance.yahoo.com - August 4 at 8:40 AM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Issues Earnings Results
www.americanbankingnews.com - August 3 at 9:21 PM
finance.yahoo.com logoSupernus Announces Record Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 7:40 AM
finance.yahoo.com logoSupernus tops Street 2Q forecasts
finance.yahoo.com - August 3 at 7:40 AM
americanbankingnews.com logoBidaskClub Lowers Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to Hold
www.americanbankingnews.com - August 2 at 7:32 PM
americanbankingnews.com logoSunTrust Banks Weighs in on Supernus Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:SUPN)
www.americanbankingnews.com - August 2 at 7:32 AM
finance.yahoo.com logoSupernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SUPN-US : August 1, 2017
finance.yahoo.com - August 2 at 7:32 AM
finance.yahoo.com logoETFs with exposure to Supernus Pharmaceuticals, Inc. : August 1, 2017
finance.yahoo.com - August 2 at 7:32 AM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 28 at 4:42 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $68.54 Million
www.americanbankingnews.com - July 20 at 3:22 PM
globenewswire.com logoSupernus to Host Second Quarter 2017 Earnings Conference Call - GlobeNewswire (press release)
globenewswire.com - July 20 at 8:13 AM
finance.yahoo.com logoSupernus to Host Second Quarter 2017 Earnings Conference Call
finance.yahoo.com - July 20 at 8:13 AM
benzinga.com logoLightning Round: Jim Cramer Advises Viewers On Chegg, Opko Health And More - Benzinga
www.benzinga.com - July 19 at 7:51 AM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 3,735 Shares
www.americanbankingnews.com - July 14 at 8:26 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Now Covered by Janney Montgomery Scott
www.americanbankingnews.com - July 14 at 9:10 AM
americanbankingnews.com logoAimmune Therapeutics (AIMT) & Supernus Pharmaceuticals (SUPN) Head-To-Head Contrast
www.americanbankingnews.com - July 13 at 12:26 PM
finance.yahoo.com logoETFs with exposure to Supernus Pharmaceuticals, Inc. : July 12, 2017
finance.yahoo.com - July 13 at 10:03 AM
americanbankingnews.com logoSupernus Pharmaceuticals Inc (NASDAQ:SUPN) PT Raised to $49.00
www.americanbankingnews.com - July 9 at 8:28 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Expected to Post FY2017 Earnings of $1.10 Per Share
www.americanbankingnews.com - July 7 at 10:52 AM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. to Post FY2018 Earnings of $1.93 Per Share, Cantor Fitzgerald Forecasts (SUPN)
www.americanbankingnews.com - July 6 at 11:50 AM
nasdaq.com logoStrange: Bullish SUPN Analysts Actually See -3.33% Downside - Nasdaq
www.nasdaq.com - July 4 at 7:43 AM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 3 at 4:58 PM
americanbankingnews.com logoReviewing Supernus Pharmaceuticals (SUPN) and TherapeuticsMD (TXMD)
www.americanbankingnews.com - July 1 at 10:04 PM
finance.yahoo.com logoETFs with exposure to Supernus Pharmaceuticals, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 7:56 AM
americanbankingnews.com logoJefferies Group Research Analysts Cut Earnings Estimates for Supernus Pharmaceuticals, Inc. (SUPN)
www.americanbankingnews.com - June 30 at 8:43 AM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Price Target Raised to $51.00 at Jefferies Group LLC
www.americanbankingnews.com - June 28 at 8:19 AM
americanbankingnews.com logoPadmanabh P. Bhatt Sells 2,556 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock
www.americanbankingnews.com - June 27 at 7:50 PM
americanbankingnews.com logoFY2018 Earnings Estimate for Supernus Pharmaceuticals, Inc. (SUPN) Issued By Cantor Fitzgerald
www.americanbankingnews.com - June 26 at 7:51 AM
americanbankingnews.com logoBidaskClub Upgrades Supernus Pharmaceuticals, Inc. (SUPN) to "Strong-Buy"
www.americanbankingnews.com - June 24 at 3:38 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $68.62 Million
www.americanbankingnews.com - June 23 at 1:00 PM
streetinsider.com logoSupernus Pharma (SUPN) Announces Partner, Shire PLC (SHPG), Granted FDA Approval for Mydayis for ADHD
www.streetinsider.com - June 22 at 1:53 PM
finance.yahoo.com logoSupernus Announces that its Partner Shire Receives FDA Approval for Mydayis™ for ADHD
finance.yahoo.com - June 22 at 1:53 PM
americanbankingnews.com logo Brokerages Expect Supernus Pharmaceuticals, Inc. (SUPN) to Announce $0.25 EPS
www.americanbankingnews.com - June 22 at 12:16 AM
finance.yahoo.com logoETFs with exposure to Supernus Pharmaceuticals, Inc. : June 19, 2017
finance.yahoo.com - June 20 at 8:16 AM
finance.yahoo.com logoSupernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 17 at 6:28 AM

Social

Chart

Supernus Pharmaceuticals (SUPN) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by MarketBeat.com Staff